Literature DB >> 10163418

Hypnotics. Drug selection by means of the System of Objectified Judgement Analysis (SOJA) method.

R Janknegt1, A van der Kuy, G Declerck, C Idzikowski.   

Abstract

Selection of hypnotics for drug formularies in The Netherlands, France and the UK is made by means of the System of Objectified Judgement Analysis (SOJA) method. The following criteria are included in the method: clinical efficacy (maximal 300 points), adverse effects (250 points), clinical documentation (150 points), cost (120 points), pharmacokinetic properties (80 points), toxicity (50 points), drug interactions (30 points) and the number of tablet strengths available (20 points). In all 3 countries, zolpidem, zopiclone and temazepam showed the highest score, followed by lormetazepam. High scores favour inclusion in formularies. Nitrazepam and loprazolam scored 75 to 130 points less than the top 3, and flunitrazepam shows the lowest score (119 to 183 points less than zolpidem, zopiclone and temazepam). Therefore, the first 3 (or 4) hypnotics are most suitable for formulary inclusion while the others are not.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10163418     DOI: 10.2165/00019053-199610020-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  38 in total

Review 1.  Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.

Authors:  R Janknegt
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

2.  Studies on the dependence-inducing potential of zopiclone and triazolam.

Authors:  K Boissl; J F Dreyfus; M Delmotte
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

3.  Effects of zopiclone and benzodiazepine hypnotics on search in short-term memory.

Authors:  Z Subhan; I Hindmarch
Journal:  Neuropsychobiology       Date:  1984       Impact factor: 2.328

Review 4.  Hypnotics. Their place in therapeutics.

Authors:  A N Nicholson
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 5.  Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.

Authors:  H D Langtry; P Benfield
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

6.  Effects of hypnotics on memory.

Authors:  A Fossen; O B Godlibsen; Y Loyning; J F Dreyfus
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

7.  Epidemiology of benzodiazepine dependence.

Authors:  W W Fleischhacker; C Barnas; B Hackenberg
Journal:  Acta Psychiatr Scand       Date:  1986-07       Impact factor: 6.392

8.  A potentially hazardous interaction between erythromycin and midazolam.

Authors:  K T Olkkola; K Aranko; H Luurila; A Hiller; L Saarnivaara; J J Himberg; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

Review 9.  Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic.

Authors:  M S Langley; S P Clissold
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

Review 10.  Rebound insomnia: its determinants and significance.

Authors:  T Roehrs; G Vogel; T Roth
Journal:  Am J Med       Date:  1990-03-02       Impact factor: 4.965

View more
  4 in total

1.  Dutch hospital drug formularies: pharmacotherapeutic variation and conservatism, but concurrence with national pharmacotherapeutic guidelines.

Authors:  R Fijn; S A Engels; J R Brouwers; R J Knaap; L T De Jong-Van den Berg
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

2.  Using health outcomes data to inform decision-making: formulary committee perspective.

Authors:  R Janknegt
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion.

Authors:  R Janknegt; A Steenhoek
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 4.  A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.

Authors:  G Hajak
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.